Friday 10th November 2017
|Text too small?|
Volpara Health Technologies, the Kiwi digital health firm listed on the ASX, narrowed its first-half loss as rising revenue put it on track to deliver faster sales growth through the remainder of the year.
The Wellington-based company yesterday reported a loss of $4.2 million, or 3 cents per share, in the six months ended Sept. 30, from a loss of $4.7 million, or 4 cents, a year earlier. Volpara lifted revenue 41 percent to $1.7 million with commercial sales up 13 percent to $1.3 million and the balance from increased research and development government grants. On an annualised recurring revenue basis, a favoured measure for software-as-a-service firms, sales rose 94 percent to $2.1 million.
"This puts the company on track to exceed its 200 percent growth target for FY18, given H2 is typically strong than H1," chief executive Ralph Highnam said in a statement to the ASX. "Our tasks are now to deliver substantial growth with more customers signing up, increasingly by word of mouth, and to deliver more services to those customers to ensure they are increasingly successful and that we return increased fees per customer."
Volpara's technology focuses on early detection of breast cancer and it went public last year, choosing the ASX over a domestic listing. The shares were sold at 50 Australian cents apiece, raising A$10 million in an initial public offering in 2016, and it went back to investors seeking another A$10 million at 60 Australian cents apiece later that year.
The shares closed at 64 Australian cents yesterday, and have edged up 0.8 percent this year.
The company increased its spending on R&D to $1.5 million in the six-month period from $1.2 million a year earlier, while sales and marketing expenses shrank to $2.6 million from $2.7 million. Operating cash burn slowed to $3.4 million from $3.8 million and the company had cash and equivalents of $1.3 million as at Sept. 30, plus a further $8 million in term deposits.
NOTE: please be advised to read full articles from Business Desk Website, you will have to pay a subscription fee on their website.
No comments yet
Supplements, skincare firm poised for reverse listing
NZX, EEX eye carbon auction opportunity
A2 Milk boss steps down, shares fall 7.7%
NZX says operating earnings will reach top of guidance
NZ dollar consolidates weekly gain of more than a US cent
NZ dollar holds gains on improved dairy, bank capital outlook
MARKET CLOSE: NZ shares gain; banks rally on Reserve Bank capital decision
NZ dollar rises; bank capital rules less harsh than expected
RBNZ relaxes capital requirements, allows preference shares, extends phase-in
NZ dollar extends gain amid mixed US data, possible trade progress